Table of Contents

company-logo

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Dividend Announcement

• UroGen Pharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on UroGen Pharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

UroGen Pharma Dividend History

UroGen Pharma Dividend Yield

UroGen Pharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing UroGen Pharma stock? Use our calculator to estimate your expected dividend yield:

UroGen Pharma Financial Ratios

P/E ratio-0.48
PEG ratio0.01
P/B ratio2.16
ROE932.03%
Payout ratio0.00%
Current ratio9.00
Quick ratio8.77
Cash Ratio3.81

UroGen Pharma Dividend FAQ

Does UroGen Pharma stock pay dividends?
UroGen Pharma does not currently pay dividends to its shareholders.
Has UroGen Pharma ever paid a dividend?
No, UroGen Pharma has no a history of paying dividends to its shareholders. UroGen Pharma is not known for its dividend payments.
Why doesn't UroGen Pharma pay dividends?
There are several potential reasons why UroGen Pharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will UroGen Pharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While UroGen Pharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is UroGen Pharma a dividend aristocrat?
UroGen Pharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is UroGen Pharma a dividend king?
UroGen Pharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is UroGen Pharma a dividend stock?
No, UroGen Pharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy UroGen Pharma stocks?
To buy UroGen Pharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy UroGen Pharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.